You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEplerenone
Accession NumberDB00700  (APRD00707)
TypeSmall Molecule
GroupsApproved
DescriptionEplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.
Structure
Thumb
Synonyms
Epoxymexrenone
Inspra
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Eplerenonetablet, film coated25 mg/1oralAvera Mc Kennan Hospital2015-06-17Not applicableUs
Eplerenonetablet, film coated50 mg/1oralGreenstone LLC2002-09-27Not applicableUs
Eplerenonetablet, film coated25 mg/1oralGreenstone LLC2002-09-27Not applicableUs
Inspratablet, film coated25 mg/1oralG.D. Searle LLC Division of Pfizer Inc2002-09-27Not applicableUs
Inspratablet, film coated50 mg/1oralG.D. Searle LLC Division of Pfizer Inc2002-09-27Not applicableUs
Inspratablet25 mgoralPfizer Canada Inc2009-05-08Not applicableCanada
Inspratablet25 mg/1oralRebel Distributors Corp2002-09-27Not applicableUs
Inspratablet50 mgoralPfizer Canada Inc2009-05-05Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Eplerenonetablet50 mg/1oralApotex Corp2008-07-30Not applicableUs
Eplerenonetablet25 mg/1oralEon Labs, Inc.2008-08-01Not applicableUs
Eplerenonetablet50 mg/1oralRebel Distributors Corp.2008-08-01Not applicableUs
Eplerenonetablet25 mg/1oralAmerican Health Packaging2015-09-01Not applicableUs
Eplerenonetablet50 mg/1oralEon Labs, Inc.2008-08-01Not applicableUs
Eplerenonetablet25 mg/1oralPhysicians Total Care, Inc.2009-09-14Not applicableUs
Eplerenonetablet25 mg/1oralUpsher Smith Laboratories, Inc.2015-03-16Not applicableUs
Eplerenonetablet25 mg/1oralApotex Corp2008-07-30Not applicableUs
Eplerenonetablet50 mg/1oralUpsher Smith Laboratories, Inc.2015-03-16Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII6995V82D0B
CAS number107724-20-9
WeightAverage: 414.4914
Monoisotopic: 414.204238692
Chemical FormulaC24H30O6
InChI KeyInChIKey=JUKPWJGBANNWMW-VWBFHTRKSA-N
InChI
InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1
IUPAC Name
methyl (1'R,2R,2'S,9'R,10'R,11'S,15'S,17'R)-2',15'-dimethyl-5,5'-dioxo-18'-oxaspiro[oxolane-2,14'-pentacyclo[8.8.0.0¹,¹⁷.0²,⁷.0¹¹,¹⁵]octadecan]-6'-ene-9'-carboxylate
SMILES
[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[[email protected]]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as spironolactones and derivatives. These are steroid lactones with a structure based on the spironolactone skeleton.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid lactones
Direct ParentSpironolactones and derivatives
Alternative Parents
Substituents
  • Spironolactone
  • Oxepane
  • Gamma butyrolactone
  • Dicarboxylic acid or derivatives
  • Methyl ester
  • Oxolane
  • Cyclic ketone
  • Lactone
  • Ketone
  • Carboxylic acid ester
  • Oxacycle
  • Organoheterocyclic compound
  • Ether
  • Oxirane
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.
PharmacodynamicsEplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.
Mechanism of actionEplerenone binds to the mineralocorticoid receptor and thereby blocks the binding of aldosterone (component of the renin-angiotensin-aldosterone-system, or RAAS). Aldosterone synthesis, which occurs primarily in the adrenal gland, is modulated by multiple factors, including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone (ACTH) and potassium. Aldosterone binds to mineralocorticoid receptors in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, blood vessels, and brain) tissues and increases blood pressure through induction of sodium reabsorption and possibly other mechanisms.
Related Articles
AbsorptionThe absolute bioavailability of eplerenone is unknown.
Volume of distribution
  • 43 to 90 L
Protein binding50%
Metabolism

Eplerenone is metabolized primarily by CYP3A4, however, no active metabolites have been identified in human plasma.

Route of eliminationNot Available
Half life4-6 hours
Clearance
  • Apparent plasma cl=10 L/hr
ToxicityThe most likely symptoms of human overdosage would be anticipated to be hypotension or hyperkalemia. However, no cases of human overdosage with eplerenone have been reported.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Eplerenone Action PathwayDrug actionSMP00135
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9839
Blood Brain Barrier+0.8556
Caco-2 permeable+0.5076
P-glycoprotein substrateSubstrate0.7017
P-glycoprotein inhibitor IInhibitor0.8166
P-glycoprotein inhibitor IIInhibitor0.8066
Renal organic cation transporterNon-inhibitor0.7209
CYP450 2C9 substrateNon-substrate0.8229
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.6978
CYP450 2C9 inhibitorNon-inhibitor0.7982
CYP450 2D6 inhibitorNon-inhibitor0.931
CYP450 2C19 inhibitorNon-inhibitor0.839
CYP450 3A4 inhibitorNon-inhibitor0.8368
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8902
Ames testNon AMES toxic0.7496
CarcinogenicityNon-carcinogens0.9441
BiodegradationNot ready biodegradable0.9891
Rat acute toxicity2.4761 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9453
hERG inhibition (predictor II)Non-inhibitor0.7742
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apotex inc
  • Sandoz inc
  • Gd searle llc
Packagers
Dosage forms
FormRouteStrength
Tabletoral25 mg/1
Tabletoral50 mg/1
Tabletoral25 mg
Tabletoral50 mg
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Prices
Unit descriptionCostUnit
Inspra 25 mg tablet4.87USD tablet
Inspra 50 mg tablet4.87USD tablet
Eplerenone 25 mg tablet4.18USD tablet
Eplerenone 50 mg tablet4.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6410054 Yes2000-06-082020-06-08Us
US6410524 Yes2000-05-052020-05-05Us
US6495165 Yes2000-06-082020-06-08Us
US6534093 Yes2000-06-082020-06-08Us
US6558707 Yes2000-06-082020-06-08Us
US6747020 Yes2000-05-052020-05-05Us
US6863902 No2000-10-102020-10-10Us
US7157101 Yes2000-06-082020-06-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySlightly solubleNot Available
logP1.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00903 mg/mLALOGPS
logP1.67ALOGPS
logP2.33ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)15.11ChemAxon
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area82.2 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity106.68 m3·mol-1ChemAxon
Polarizability43.79 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Bhaskar Reddy Guntoori, Svetoslav S. Bratovanov, Mohamed Ibrahim Zaki, Elena Bejan, Stephen E. Horne, “Process for the preparation and purification of eplerenone.” U.S. Patent US20080234478, issued September 25, 2008.

US20080234478
General ReferencesNot Available
External Links
ATC CodesC03DA04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (136 KB)
MSDSDownload (68.2 KB)
Interactions
Drug Interactions
Drug
AcebutololThe risk or severity of adverse effects can be increased when Eplerenone is combined with Acebutolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Eplerenone.
AcetazolamideThe risk or severity of adverse effects can be increased when Eplerenone is combined with Acetazolamide.
AcetyldigitoxinThe therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Eplerenone.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Eplerenone.
AdapaleneAdapalene may decrease the antihypertensive activities of Eplerenone.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Eplerenone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Eplerenone.
AliskirenThe risk or severity of adverse effects can be increased when Eplerenone is combined with Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Eplerenone.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Eplerenone.
AmiodaroneThe serum concentration of Eplerenone can be increased when it is combined with Amiodarone.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Eplerenone.
Ammonium chlorideThe risk or severity of adverse effects can be increased when Eplerenone is combined with Ammonium chloride.
AmobarbitalAmobarbital may increase the hypotensive activities of Eplerenone.
Amyl NitriteThe risk or severity of adverse effects can be increased when Eplerenone is combined with Amyl Nitrite.
AntipyrineAntipyrine may decrease the antihypertensive activities of Eplerenone.
ApraclonidineThe risk or severity of adverse effects can be increased when Eplerenone is combined with Apraclonidine.
ApremilastApremilast may decrease the antihypertensive activities of Eplerenone.
AprepitantThe serum concentration of Eplerenone can be increased when it is combined with Aprepitant.
ArdeparinArdeparin may increase the hyperkalemic activities of Eplerenone.
AripiprazoleAripiprazole may increase the hypotensive activities of Eplerenone.
AtazanavirThe serum concentration of Eplerenone can be increased when it is combined with Atazanavir.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Eplerenone.
AtomoxetineThe metabolism of Eplerenone can be decreased when combined with Atomoxetine.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Eplerenone.
AzelastineAzelastine may decrease the antihypertensive activities of Eplerenone.
Azilsartan medoxomilEplerenone may increase the hyperkalemic activities of Azilsartan medoxomil.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Eplerenone.
BalsalazideBalsalazide may decrease the antihypertensive activities of Eplerenone.
BarbitalBarbital may increase the hypotensive activities of Eplerenone.
BemiparinBemiparin may increase the hyperkalemic activities of Eplerenone.
BenazeprilEplerenone may increase the hyperkalemic activities of Benazepril.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Eplerenone.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Eplerenone.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Eplerenone.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Eplerenone.
BexaroteneThe serum concentration of Eplerenone can be decreased when it is combined with Bexarotene.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Eplerenone.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Eplerenone.
BoceprevirThe serum concentration of Eplerenone can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Eplerenone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Eplerenone can be decreased when it is combined with Bosentan.
BretyliumThe risk or severity of adverse effects can be increased when Eplerenone is combined with Bretylium.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Eplerenone.
BromfenacBromfenac may decrease the antihypertensive activities of Eplerenone.
BumetanideThe risk or severity of adverse effects can be increased when Eplerenone is combined with Bumetanide.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Eplerenone.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Eplerenone.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Eplerenone.
CanagliflozinThe risk or severity of adverse effects can be increased when Eplerenone is combined with Canagliflozin.
CandesartanEplerenone may increase the hyperkalemic activities of Candesartan.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Eplerenone.
CandoxatrilEplerenone may increase the hyperkalemic activities of Candoxatril.
CaptoprilEplerenone may increase the hyperkalemic activities of Captopril.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Eplerenone.
CarbamazepineThe metabolism of Eplerenone can be increased when combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Eplerenone.
CarprofenCarprofen may decrease the antihypertensive activities of Eplerenone.
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Eplerenone.
CarvedilolThe risk or severity of adverse effects can be increased when Eplerenone is combined with Carvedilol.
CastanospermineCastanospermine may decrease the antihypertensive activities of Eplerenone.
CelecoxibCelecoxib may decrease the antihypertensive activities of Eplerenone.
CeritinibThe serum concentration of Eplerenone can be increased when it is combined with Ceritinib.
CertoparinCertoparin may increase the hyperkalemic activities of Eplerenone.
ChloroquineChloroquine may decrease the antihypertensive activities of Eplerenone.
ChlorothiazideThe risk or severity of adverse effects can be increased when Eplerenone is combined with Chlorothiazide.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Eplerenone.
CilazaprilEplerenone may increase the hyperkalemic activities of Cilazapril.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Eplerenone.
ClarithromycinThe serum concentration of Eplerenone can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Eplerenone can be decreased when combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Eplerenone is combined with Clevidipine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Eplerenone.
ClonixinClonixin may decrease the antihypertensive activities of Eplerenone.
ClotrimazoleThe metabolism of Eplerenone can be decreased when combined with Clotrimazole.
CobicistatThe serum concentration of Eplerenone can be increased when it is combined with Cobicistat.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Eplerenone.
ConivaptanThe serum concentration of Eplerenone can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Eplerenone can be decreased when combined with Crizotinib.
CyclosporineEplerenone may increase the hyperkalemic activities of Cyclosporine.
CyclosporineThe metabolism of Eplerenone can be decreased when combined with Cyclosporine.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Eplerenone.
DabrafenibThe serum concentration of Eplerenone can be decreased when it is combined with Dabrafenib.
DalteparinDalteparin may increase the hyperkalemic activities of Eplerenone.
DapagliflozinThe risk or severity of adverse effects can be increased when Eplerenone is combined with Dapagliflozin.
DarunavirThe serum concentration of Eplerenone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Eplerenone can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Eplerenone can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Eplerenone can be decreased when combined with Delavirdine.
DeslanosideThe therapeutic efficacy of Deslanoside can be decreased when used in combination with Eplerenone.
DexamethasoneThe serum concentration of Eplerenone can be decreased when it is combined with Dexamethasone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Eplerenone.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Eplerenone.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Eplerenone.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Eplerenone.
DiclofenacDiclofenac may decrease the antihypertensive activities of Eplerenone.
DiclofenamideThe risk or severity of adverse effects can be increased when Eplerenone is combined with Diclofenamide.
DiflunisalDiflunisal may decrease the antihypertensive activities of Eplerenone.
DigitoxinThe therapeutic efficacy of Digitoxin can be decreased when used in combination with Eplerenone.
DigoxinThe therapeutic efficacy of Digoxin can be decreased when used in combination with Eplerenone.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Eplerenone.
DihydroergotamineThe metabolism of Eplerenone can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Eplerenone.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Eplerenone.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Eplerenone.
DinutuximabThe risk or severity of adverse effects can be increased when Eplerenone is combined with Dinutuximab.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Eplerenone.
DipyridamoleThe risk or severity of adverse effects can be increased when Eplerenone is combined with Dipyridamole.
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Eplerenone.
DoxycyclineThe metabolism of Eplerenone can be decreased when combined with Doxycycline.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Eplerenone.
DronedaroneThe metabolism of Eplerenone can be decreased when combined with Dronedarone.
DrospirenoneDrospirenone may increase the hyperkalemic activities of Eplerenone.
DroxicamDroxicam may decrease the antihypertensive activities of Eplerenone.
DuloxetineEplerenone may increase the orthostatic hypotensive activities of Duloxetine.
EfavirenzThe serum concentration of Eplerenone can be decreased when it is combined with Efavirenz.
EmpagliflozinThe risk or severity of adverse effects can be increased when Eplerenone is combined with Empagliflozin.
EnalaprilEplerenone may increase the hyperkalemic activities of Enalapril.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Eplerenone.
EnalaprilatEplerenone may increase the hyperkalemic activities of Enalaprilat.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Eplerenone.
EnzalutamideThe serum concentration of Eplerenone can be decreased when it is combined with Enzalutamide.
EpirizoleEpirizole may decrease the antihypertensive activities of Eplerenone.
EprosartanEplerenone may increase the hyperkalemic activities of Eprosartan.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Eplerenone.
ErythromycinThe metabolism of Eplerenone can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Eplerenone can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Eplerenone.
Etacrynic acidThe risk or severity of adverse effects can be increased when Eplerenone is combined with Etacrynic acid.
EtanerceptEtanercept may decrease the antihypertensive activities of Eplerenone.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Eplerenone.
EtodolacEtodolac may decrease the antihypertensive activities of Eplerenone.
EtofenamateEtofenamate may decrease the antihypertensive activities of Eplerenone.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Eplerenone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Eplerenone.
EtravirineThe serum concentration of Eplerenone can be decreased when it is combined with Etravirine.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Eplerenone.
exisulindexisulind may decrease the antihypertensive activities of Eplerenone.
FelodipineThe risk or severity of adverse effects can be increased when Eplerenone is combined with Felodipine.
FenbufenFenbufen may decrease the antihypertensive activities of Eplerenone.
FenoprofenFenoprofen may decrease the antihypertensive activities of Eplerenone.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Eplerenone.
FloctafenineFloctafenine may decrease the antihypertensive activities of Eplerenone.
FluconazoleThe metabolism of Eplerenone can be decreased when combined with Fluconazole.
FlunixinFlunixin may decrease the antihypertensive activities of Eplerenone.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Eplerenone.
FluvoxamineThe metabolism of Eplerenone can be decreased when combined with Fluvoxamine.
ForasartanEplerenone may increase the hyperkalemic activities of Forasartan.
FosamprenavirThe metabolism of Eplerenone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Eplerenone can be increased when it is combined with Fosaprepitant.
FosinoprilEplerenone may increase the hyperkalemic activities of Fosinopril.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Eplerenone.
FosphenytoinThe metabolism of Eplerenone can be increased when combined with Fosphenytoin.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Eplerenone.
Fusidic AcidThe serum concentration of Eplerenone can be increased when it is combined with Fusidic Acid.
GuanfacineThe risk or severity of adverse effects can be increased when Eplerenone is combined with Guanfacine.
HeparinHeparin may increase the hyperkalemic activities of Eplerenone.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Eplerenone.
HexobarbitalHexobarbital may increase the hypotensive activities of Eplerenone.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Eplerenone.
HydralazineThe risk or severity of adverse effects can be increased when Eplerenone is combined with Hydralazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Eplerenone is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Eplerenone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Eplerenone.
IbuprofenIbuprofen may decrease the antihypertensive activities of Eplerenone.
IbuproxamIbuproxam may decrease the antihypertensive activities of Eplerenone.
IcatibantIcatibant may decrease the antihypertensive activities of Eplerenone.
IdelalisibThe serum concentration of Eplerenone can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Eplerenone can be decreased when combined with Imatinib.
IndapamideThe risk or severity of adverse effects can be increased when Eplerenone is combined with Indapamide.
IndinavirThe serum concentration of Eplerenone can be increased when it is combined with Indinavir.
IndomethacinIndomethacin may decrease the antihypertensive activities of Eplerenone.
IndoprofenIndoprofen may decrease the antihypertensive activities of Eplerenone.
IrbesartanEplerenone may increase the hyperkalemic activities of Irbesartan.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Eplerenone.
IsavuconazoniumThe metabolism of Eplerenone can be decreased when combined with Isavuconazonium.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Eplerenone is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Eplerenone is combined with Isosorbide Mononitrate.
IsoxicamIsoxicam may decrease the antihypertensive activities of Eplerenone.
IsoxsuprineThe risk or severity of adverse effects can be increased when Eplerenone is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Eplerenone.
ItraconazoleThe serum concentration of Eplerenone can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Eplerenone can be increased when it is combined with Ivacaftor.
KebuzoneKebuzone may decrease the antihypertensive activities of Eplerenone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Eplerenone.
KetoconazoleThe serum concentration of Eplerenone can be increased when it is combined with Ketoconazole.
KetoprofenKetoprofen may decrease the antihypertensive activities of Eplerenone.
KetorolacKetorolac may decrease the antihypertensive activities of Eplerenone.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Eplerenone.
LeflunomideLeflunomide may decrease the antihypertensive activities of Eplerenone.
LevobunololThe risk or severity of adverse effects can be increased when Eplerenone is combined with Levobunolol.
LevodopaEplerenone may increase the orthostatic hypotensive activities of Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Eplerenone.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Eplerenone.
LisinoprilEplerenone may increase the hyperkalemic activities of Lisinopril.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Eplerenone.
LithiumThe serum concentration of Lithium can be increased when it is combined with Eplerenone.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Eplerenone.
LopinavirThe serum concentration of Eplerenone can be increased when it is combined with Lopinavir.
LornoxicamLornoxicam may decrease the antihypertensive activities of Eplerenone.
LosartanEplerenone may increase the hyperkalemic activities of Losartan.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Eplerenone.
LovastatinThe metabolism of Eplerenone can be decreased when combined with Lovastatin.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Eplerenone.
LuliconazoleThe serum concentration of Eplerenone can be increased when it is combined with Luliconazole.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Eplerenone.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Eplerenone.
MannitolThe risk or severity of adverse effects can be increased when Eplerenone is combined with Mannitol.
MasoprocolMasoprocol may decrease the antihypertensive activities of Eplerenone.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Eplerenone.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Eplerenone.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Eplerenone.
MeloxicamMeloxicam may decrease the antihypertensive activities of Eplerenone.
MesalazineMesalazine may decrease the antihypertensive activities of Eplerenone.
MetamizoleMetamizole may decrease the antihypertensive activities of Eplerenone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Eplerenone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Eplerenone.
MethazolamideThe risk or severity of adverse effects can be increased when Eplerenone is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Eplerenone.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Eplerenone.
MethyldopaThe risk or severity of adverse effects can be increased when Eplerenone is combined with Methyldopa.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Eplerenone.
MetipranololThe risk or severity of adverse effects can be increased when Eplerenone is combined with Metipranolol.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Eplerenone.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Eplerenone.
MifepristoneThe metabolism of Eplerenone can be decreased when combined with Mifepristone.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Eplerenone.
MitotaneThe serum concentration of Eplerenone can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Eplerenone can be decreased when it is combined with Modafinil.
MoexiprilEplerenone may increase the hyperkalemic activities of Moexipril.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Eplerenone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Eplerenone.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Eplerenone.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Eplerenone.
NabumetoneNabumetone may decrease the antihypertensive activities of Eplerenone.
NadololThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nadolol.
NadroparinNadroparin may increase the hyperkalemic activities of Eplerenone.
NafcillinThe serum concentration of Eplerenone can be decreased when it is combined with Nafcillin.
NaftifineNaftifine may decrease the antihypertensive activities of Eplerenone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Eplerenone.
NaproxenNaproxen may decrease the antihypertensive activities of Eplerenone.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Eplerenone.
NebivololThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nebivolol.
NefazodoneThe serum concentration of Eplerenone can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Eplerenone can be increased when it is combined with Nelfinavir.
NepafenacNepafenac may decrease the antihypertensive activities of Eplerenone.
NesiritideThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nesiritide.
NetupitantThe serum concentration of Eplerenone can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Eplerenone can be decreased when combined with Nevirapine.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Eplerenone.
NicorandilNicorandil may increase the hypotensive activities of Eplerenone.
NifedipineThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nifedipine.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Eplerenone.
NilotinibThe metabolism of Eplerenone can be decreased when combined with Nilotinib.
NimesulideNimesulide may decrease the antihypertensive activities of Eplerenone.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Eplerenone.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Eplerenone.
NitrofurantoinNitrofurantoin may increase the hyperkalemic activities of Eplerenone.
NitroglycerinThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nitroglycerin.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Eplerenone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Eplerenone.
OlaparibThe metabolism of Eplerenone can be decreased when combined with Olaparib.
OlmesartanEplerenone may increase the hyperkalemic activities of Olmesartan.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Eplerenone.
OlopatadineOlopatadine may decrease the antihypertensive activities of Eplerenone.
OlsalazineOlsalazine may decrease the antihypertensive activities of Eplerenone.
OmapatrilatEplerenone may increase the hyperkalemic activities of Omapatrilat.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Eplerenone.
OrgoteinOrgotein may decrease the antihypertensive activities of Eplerenone.
OsimertinibThe serum concentration of Eplerenone can be increased when it is combined with Osimertinib.
OuabainThe therapeutic efficacy of Ouabain can be decreased when used in combination with Eplerenone.
OxaprozinOxaprozin may decrease the antihypertensive activities of Eplerenone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Eplerenone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Eplerenone.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Eplerenone.
PalbociclibThe serum concentration of Eplerenone can be increased when it is combined with Palbociclib.
PapaverineThe risk or severity of adverse effects can be increased when Eplerenone is combined with Papaverine.
ParecoxibParecoxib may decrease the antihypertensive activities of Eplerenone.
ParnaparinParnaparin may increase the hyperkalemic activities of Eplerenone.
PenbutololThe risk or severity of adverse effects can be increased when Eplerenone is combined with Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Eplerenone.
PentobarbitalPentobarbital may increase the hypotensive activities of Eplerenone.
PerindoprilEplerenone may increase the hyperkalemic activities of Perindopril.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Eplerenone.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Eplerenone.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Eplerenone.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Eplerenone.
PhenytoinThe metabolism of Eplerenone can be increased when combined with Phenytoin.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Eplerenone.
PindololThe risk or severity of adverse effects can be increased when Eplerenone is combined with Pindolol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Eplerenone.
PiroxicamPiroxicam may decrease the antihypertensive activities of Eplerenone.
PosaconazoleThe serum concentration of Eplerenone can be increased when it is combined with Posaconazole.
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Eplerenone.
PrimidonePrimidone may increase the hypotensive activities of Eplerenone.
PropacetamolPropacetamol may decrease the antihypertensive activities of Eplerenone.
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Eplerenone.
PTC299PTC299 may decrease the antihypertensive activities of Eplerenone.
QuetiapineThe risk or severity of adverse effects can be increased when Eplerenone is combined with Quetiapine.
QuinaprilEplerenone may increase the hyperkalemic activities of Quinapril.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Eplerenone.
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Eplerenone.
RamiprilEplerenone may increase the hyperkalemic activities of Ramipril.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Eplerenone.
RanolazineThe metabolism of Eplerenone can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Eplerenone.
RescinnamineEplerenone may increase the hyperkalemic activities of Rescinnamine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Eplerenone.
ResveratrolResveratrol may decrease the antihypertensive activities of Eplerenone.
ReviparinReviparin may increase the hyperkalemic activities of Eplerenone.
RifabutinThe metabolism of Eplerenone can be increased when combined with Rifabutin.
RifampicinThe metabolism of Eplerenone can be increased when combined with Rifampicin.
RifapentineThe metabolism of Eplerenone can be increased when combined with Rifapentine.
RiociguatThe risk or severity of adverse effects can be increased when Eplerenone is combined with Riociguat.
RisperidoneEplerenone may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Eplerenone can be increased when it is combined with Ritonavir.
RofecoxibRofecoxib may decrease the antihypertensive activities of Eplerenone.
SalicylamideSalicylamide may decrease the antihypertensive activities of Eplerenone.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Eplerenone.
SalsalateSalsalate may decrease the antihypertensive activities of Eplerenone.
SaprisartanEplerenone may increase the hyperkalemic activities of Saprisartan.
SaquinavirThe serum concentration of Eplerenone can be increased when it is combined with Saquinavir.
SaralasinEplerenone may increase the hyperkalemic activities of Saralasin.
SecobarbitalSecobarbital may increase the hypotensive activities of Eplerenone.
SeratrodastSeratrodast may decrease the antihypertensive activities of Eplerenone.
SildenafilThe metabolism of Eplerenone can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Eplerenone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Eplerenone can be increased when it is combined with Simeprevir.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Eplerenone.
SpiraprilEplerenone may increase the hyperkalemic activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Eplerenone.
SRT501SRT501 may decrease the antihypertensive activities of Eplerenone.
St. John's WortThe serum concentration of Eplerenone can be decreased when it is combined with St. John&#39;s Wort.
StiripentolThe serum concentration of Eplerenone can be increased when it is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Eplerenone.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Eplerenone.
SulfisoxazoleThe metabolism of Eplerenone can be decreased when combined with Sulfisoxazole.
SulindacSulindac may decrease the antihypertensive activities of Eplerenone.
SuprofenSuprofen may decrease the antihypertensive activities of Eplerenone.
TacrolimusEplerenone may increase the hyperkalemic activities of Tacrolimus.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Eplerenone.
TasosartanEplerenone may increase the hyperkalemic activities of Tasosartan.
TelaprevirThe serum concentration of Eplerenone can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Eplerenone can be increased when it is combined with Telithromycin.
TelmisartanEplerenone may increase the hyperkalemic activities of Telmisartan.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Eplerenone.
TemocaprilEplerenone may increase the hyperkalemic activities of Temocapril.
TenoxicamTenoxicam may decrease the antihypertensive activities of Eplerenone.
TepoxalinTepoxalin may decrease the antihypertensive activities of Eplerenone.
TerazosinThe risk or severity of adverse effects can be increased when Eplerenone is combined with Terazosin.
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Eplerenone.
ThiamylalThiamylal may increase the hypotensive activities of Eplerenone.
ThiopentalThiopental may increase the hypotensive activities of Eplerenone.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Eplerenone.
TiclopidineThe metabolism of Eplerenone can be decreased when combined with Ticlopidine.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Eplerenone.
TinzaparinTinzaparin may increase the hyperkalemic activities of Eplerenone.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Eplerenone.
TocilizumabThe serum concentration of Eplerenone can be decreased when it is combined with Tocilizumab.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Eplerenone.
TolmetinTolmetin may decrease the antihypertensive activities of Eplerenone.
TolvaptanTolvaptan may increase the hyperkalemic activities of Eplerenone.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Eplerenone.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Eplerenone.
TrandolaprilEplerenone may increase the hyperkalemic activities of Trandolapril.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Eplerenone.
TranilastTranilast may decrease the antihypertensive activities of Eplerenone.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Eplerenone.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Eplerenone.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Eplerenone.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Eplerenone.
ValsartanEplerenone may increase the hyperkalemic activities of Valsartan.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Eplerenone.
VenlafaxineThe metabolism of Eplerenone can be decreased when combined with Venlafaxine.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Eplerenone.
VoriconazoleThe serum concentration of Eplerenone can be increased when it is combined with Voriconazole.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Eplerenone.
ZileutonZileuton may decrease the antihypertensive activities of Eplerenone.
ZiprasidoneThe metabolism of Eplerenone can be decreased when combined with Ziprasidone.
ZomepiracZomepirac may decrease the antihypertensive activities of Eplerenone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels.
Gene Name:
NR3C2
Uniprot ID:
P08235
Molecular Weight:
107066.575 Da
References
  1. Moore TD, Nawarskas JJ, Anderson JR: Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Heart Dis. 2003 Sep-Oct;5(5):354-63. [PubMed:14503934 ]
  2. Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J: Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol. 2003 Nov 5;42(9):1666-73. [PubMed:14607457 ]
  3. Rogerson FM, Yao Y, Smith BJ, Fuller PJ: Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor. Clin Exp Pharmacol Physiol. 2004 Oct;31(10):704-9. [PubMed:15554912 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 11-beta-monooxygenase activity
Specific Function:
Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name:
CYP11B2
Uniprot ID:
P19099
Molecular Weight:
57559.62 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 01, 2016 03:35